Francisco Cruz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9360540/publications.pdf

Version: 2024-02-01

168	6,562	53660 45	74018 75
papers	citations	h-index	g-index

231	231	231	4626
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial. European Urology, 2011, 60, 742-750.	0.9	410
2	EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. European Urology, 2012, 62, 1130-1142.	0.9	251
3	EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. European Urology, 2018, 73, 596-609.	0.9	237
4	EAU Guidelines on Surgical Treatment of Urinary Incontinence. European Urology, 2012, 62, 1118-1129.	0.9	225
5	Anandamide-Evoked Activation of Vanilloid Receptor 1 Contributes to the Development of Bladder Hyperreflexia and Nociceptive Transmission to Spinal Dorsal Horn Neurons in Cystitis. Journal of Neuroscience, 2004, 24, 11253-11263.	1.7	182
6	Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis. European Urology, 2010, 58, 360-365.	0.9	169
7	Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 2017, 72, 424-431.	0.9	165
8	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Current Opinion in Urology, 2009, 19, 380-394.	0.9	161
9	TRPV1: a therapeutic target for novel analgesic drugs?. Trends in Molecular Medicine, 2006, 12, 545-554.	3.5	154
10	Pregnancy and Cholelithiasis: Pathogenesis and Natural Course of Gallstones Diagnosed in Early Puerperium. Hepatology, 1993, 17, 1-4.	3.6	152
11	TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 287-299.	1.4	152
12	The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. Journal of Urology, 2002, 168, 575-579.	0.2	148
13	Desensitization of Bladder Sensory Fibers by Intravesical Capsaicin has Long Lasting Clinical and Urodynamic Effects in Patients With Hyperactive or Hypersensitive Bladder Dysfunction. Journal of Urology, 1997, 157, 585-589.	0.2	125
14	Transient Receptor Potential Vanilloid Subfamily 1 is Essential for the Generation of Noxious Bladder Input and Bladder Overactivity in Cystitis. Journal of Urology, 2007, 177, 1537-1541.	0.2	108
15	GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models. Journal of Urology, 2009, 181, 379-386.	0.2	91
16	Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder. European Urology, 2010, 57, 884-890.	0.9	89
17	Intermediateâ€term results, up to 4â€ƒyears, of a boneâ€anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. BJU International, 2009, 103, 500-504.	1.3	80
18	Neurotrophins as regulators of urinary bladder function. Nature Reviews Urology, 2012, 9, 628-637.	1.9	78

#	Article	IF	Citations
19	OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology. Advances in Therapy, 2013, 30, 819-833.	1.3	77
20	Vanilloid receptor and detrusor instability. Urology, 2002, 59, 51-60.	0.5	75
21	Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain, 2005, 116, 411-419.	2.0	74
22	The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction. Current Neuropharmacology, 2007, 5, 244-252.	1.4	73
23	Bladder function after radical hysterectomy for cervical cancer. Neurourology and Urodynamics, 2015, 34, 309-315.	0.8	73
24	Mechanisms involved in new therapies for overactive bladder. Urology, 2004, 63, 65-73.	0.5	72
25	Spread of OnabotulinumtoxinA After Bladder Injection. Experimental Study Using the Distribution of Cleaved SNAP-25 as the Marker of the Toxin Action. European Urology, 2012, 61, 1178-1184.	0.9	72
26	Persistent Therapeutic Effect of Repeated Injections of Onabotulinum Toxin A in Refractory Bladder Pain Syndrome/Interstitial Cystitis. Journal of Urology, 2013, 189, 548-553.	0.2	72
27	Intraprostatic Botulinum Toxin Type A Injection in Patients Unfit for Surgery Presenting with Refractory Urinary Retention and Benign Prostatic Enlargement. Effect on Prostate Volume and Micturition Resumption. European Urology, 2008, 53, 153-159.	0.9	70
28	Exploratory Study Assessing Efficacy and Complications of TVT-O, TVT-Secur, and Mini-Arc: Results at 12-Month Follow-Up. European Urology, 2011, 59, 940-944.	0.9	69
29	Urinary Neurotrophic Factors in Healthy Individuals and Patients with Overactive Bladder. Journal of Urology, 2013, 189, 359-365.	0.2	68
30	Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourology and Urodynamics, 2007, 26, 920-927.	0.8	67
31	Targets for botulinum toxin in the lower urinary tract. Neurourology and Urodynamics, 2014, 33, 31-38.	0.8	66
32	Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU International, 2004, 94, 153-157.	1.3	63
33	Urodynamic Effect of Intravesical Resiniferatoxin in Patients with Neurogenic Detrusor Overactivity of Spinal Origin: Results of a Double-Blind Randomized Placebo-Controlled Trial. European Urology, 2005, 48, 650-655.	0.9	62
34	Peptide immunoreactivity and ultrastructure of rat urinary bladder nerve fibers after topical desensitization by capsaicin or resiniferatoxin. Autonomic Neuroscience: Basic and Clinical, 2000, 86, 37-46.	1.4	61
35	Functional Transient Receptor Potential Vanilloid 1 is Expressed in Human Urothelial Cells. Journal of Urology, 2009, 182, 2944-2950.	0.2	61
36	Current medical treatment of lower urinary tract symptoms/BPH. Current Opinion in Urology, 2014, 24, 21-28.	0.9	56

#	Article	IF	Citations
37	Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. European Journal of Neuroscience, 2005, 21, 773-781.	1.2	54
38	Spinal Cord Injury and Bladder Dysfunction: New Ideas about an Old Problem. Scientific World Journal, The, 2011, 11, 214-234.	0.8	54
39	The Distribution of Sensory Fibers Immunoreactive for the TRPV1 (Capsaicin) Receptor in the Human Prostate. European Urology, 2005, 48, 162-167.	0.9	50
40	Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. European Urology, 2009, 56, 134-141.	0.9	50
41	Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool?. Advances in Urology, 2011, 2011, 1-7.	0.6	50
42	Future Direction in Pharmacotherapy for Non-neurogenic Male Lower Urinary Tract Symptoms. European Urology, 2013, 64, 610-621.	0.9	50
43	Ulcerative and Nonulcerative Forms of Bladder Pain Syndrome/Interstitial Cystitis Do Not Differ in Symptom Intensity or Response to Onabotulinum Toxin A. Urology, 2014, 83, 1030-1034.	0.5	50
44	Insulin induces cobalt uptake in a subpopulation of rat cultured primary sensory neurons. European Journal of Neuroscience, 2003, 18, 2477-2486.	1.2	49
45	Intravesical resiniferatoxin desensitizes rat bladder sensory fibres without causing intense noxious excitation. A c-fos study. European Journal of Pharmacology, 1999, 378, 17-22.	1.7	47
46	IntratrigonalOnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial. Journal of Urology, 2018, 199, 998-1003.	0.2	44
47	Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World Journal of Urology, 2014, 32, 1119-1125.	1.2	43
48	Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. European Urology, 2020, 77, 119-128.	0.9	43
49	Activation of the c-fosProto-Oncogene in the Spinal Cord Following Noxious Stimulation of the Urinary Bladder. Somatosensory & Motor Research, 1994, 11, 319-325.	0.4	42
50	Neurochemical characterization of insulin receptor-expressing primary sensory neurons in wild-type and vanilloid type 1 transient receptor potential receptor knockout mice. Journal of Comparative Neurology, 2007, 503, 334-347.	0.9	40
51	The Role of Brain-Derived Neurotrophic Factor (BDNF) in the Development of Neurogenic Detrusor Overactivity (NDO). Journal of Neuroscience, 2015, 35, 2146-2160.	1.7	38
52	Betaâ€3 adrenergic receptor is expressed in acetylcholineâ€containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourology and Urodynamics, 2017, 36, 1972-1980.	0.8	38
53	Surveillance and management of urologic complications after spinal cord injury. World Journal of Urology, 2018, 36, 1545-1553.	1.2	38
54	Bladder C-Fiber Desensitization Induces a Long-Lasting Improvement of BPH-Associated Storage LUTS: A Pilot Study. European Urology, 2004, 46, 88-94.	0.9	36

#	Article	IF	Citations
55	Treatment of male stress urinary incontinence with the adjustable transobturator male system: Outcomes of a multiâ€center Iberian study. Neurourology and Urodynamics, 2018, 37, 1458-1466.	0.8	36
56	Shortâ€term assessment of a tensionâ€free vaginal tape for treating female stress urinary incontinence. BJU International, 2009, 104, 225-228.	1.3	35
57	Lower Urinary Tract Symptoms and Aging: The Impact of Chronic Bladder Ischemia on Overactive Bladder Syndrome. Urologia Internationalis, 2015, 95, 373-379.	0.6	35
58	Urinary Biomarkers in Overactive Bladder: Revisiting the Evidence in 2019. European Urology Focus, 2019, 5, 329-336.	1.6	35
59	Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urology, 2009, 9, 9.	0.6	34
60	Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Neurourology and Urodynamics, 2014, 33, S26-31.	0.8	34
61	Desensitization follows excitation of bladder primary afferents by intravesical capsaicin, as shown by c- fos activation in the rat spinal cord. Pain, 1996, 64, 553-557.	2.0	32
62	Bladder sensory desensitization decreases urinary urgency. BMC Urology, 2007, 7, 9.	0.6	32
63	Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Experimental Neurology, 2008, 214, 301-308.	2.0	32
64	Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist. Autonomic Neuroscience: Basic and Clinical, 2012, 166, 35-38.	1.4	31
65	Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourology and Urodynamics, 2015, 34, 489-496.	0.8	31
66	Biomarkers of spinal cord injury and ensuing bladder dysfunction. Advanced Drug Delivery Reviews, 2015, 82-83, 153-159.	6.6	31
67	Effect of OnabotulinumtoxinA on Intramural Parasympathetic Ganglia: An Experimental Study in the Guinea Pig Bladder. Journal of Urology, 2012, 187, 1121-1126.	0.2	30
68	An integrated program of extracorporeal membrane oxygenation (ECMO) assisted cardiopulmonary resuscitation and uncontrolled donation after circulatory determination of death in refractory cardiac arrest. Resuscitation, 2018, 133, 88-94.	1.3	30
69	Characterization of VEGF and Angiopoietins Expression in Human Corpus Cavernosum during Aging. Journal of Sexual Medicine, 2010, 7, 1410-1418.	0.3	29
70	The water avoidance stress induces bladder pain due to a prolonged alpha1A adrenoceptor stimulation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 839-844.	1.4	28
71	Transient receptor potential vanilloid 1 mediates nerve growth factorâ€induced bladder hyperactivity and noxious input. BJU International, 2012, 110, E422-8.	1.3	27
72	A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. Thyroid, 2017, 27, 1058-1067.	2.4	27

#	Article	IF	Citations
73	Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Experimental Neurology, 2006, 200, 66-73.	2.0	26
74	The activation of the ERK pathway contributes to the spinal c-fosexpression observed after noxious bladder stimulation. Somatosensory & Motor Research, 2007, 24, 15-20.	0.4	26
75	Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opinion on Pharmacotherapy, 2012, 13, 2085-2096.	0.9	26
76	Coâ€administration of transient receptor potential vanilloid 4 (<scp>TRPV4</scp>) and <scp>TRPV1</scp> antagonists potentiate the effect of each drug in a rat model of cystitis. BJU International, 2015, 115, 452-460.	1.3	26
77	Botulinum toxin in the management of lower urinary tract dysfunction: contemporary update. Current Opinion in Urology, 2004, 14, 329-334.	0.9	25
78	VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCG. BMC Physiology, 2011, 11, 16.	3.6	25
79	Biomarkers in lower urinary tract symptoms/overactive bladder. Current Opinion in Urology, 2014, 24, 352-357.	0.9	25
80	Management of Female and Functional Urology Patients During the COVID Pandemic. European Urology Focus, 2020, 6, 1049-1057.	1.6	25
81	LIDOCAINE PREVENTS NOXIOUS EXCITATION OF BLADDER AFFERENTS INDUCED BY INTRAVESICAL CAPSAICIN WITHOUT INTERFERING WITH THE ENSUING SENSORY DESENSITIZATION: AN EXPERIMENTAL STUDY IN THE RAT. Journal of Urology, 1998, 159, 567-570.	0.2	24
82	Nerve growth factor regulates galanin and c-jun overexpression occurring in dorsal root ganglion cells after intravesical resiniferatoxin application. Brain Research, 2002, 951, 264-269.	1.1	24
83	Singleâ€incision sling system as primary treatment of female stress urinary incontinence: prospective 12 months data from a single institution. BJU International, 2011, 108, 1616-1621.	1.3	24
84	Immunocytochemical staining of neuropeptides in terminal arborization of primary afferent fibers anterogradely labeled and identified at light and electron microscopic levels. Journal of Neuroscience Methods, 1992, 42, 105-113.	1.3	23
85	Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats. Experimental Neurology, 2016, 285, 159-166.	2.0	22
86	Botulinum toxin treatment for bladder dysfunction. International Journal of Urology, 2013, 20, 956-962.	0.5	20
87	Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU International, 2011, 107, 1950-1954.	1.3	19
88	Are All Metabolic Syndrome Components Responsible for Penile Hemodynamics Impairment in Patients with Erectile Dysfunction? The Role of Body Fat Mass Assessment. Journal of Sexual Medicine, 2011, 8, 831-839.	0.3	19
89	Cystitis is associated with TRPV1b-downregulation in rat dorsal root ganglia. NeuroReport, 2008, 19, 1469-1472.	0.6	18
90	Recurrent Urinary Tract Infections: Uro-VaxomÂ®, a New Alternative. European Urology Supplements, 2009, 8, 762-768.	0.1	18

#	Article	IF	Citations
91	Adjustable Transobturator Male System after Failed Surgical Devices for Male Stress Urinary Incontinence: A Feasibility Study. Urologia Internationalis, 2018, 101, 106-113.	0.6	18
92	N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology, 2009, 56, 676-683.	2.0	17
93	Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. Current Opinion in Urology, 2009, 19, 347-352.	0.9	17
94	Patient satisfaction with adjustable transobturator male system in the Iberian multicenter study. World Journal of Urology, 2019, 37, 2189-2197.	1.2	17
95	Longâ€term outcome of adjustable transobturator male system for stress urinary incontinence in the Iberian multicentre study. Neurourology and Urodynamics, 2020, 39, 1737-1745.	0.8	17
96	Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2). European Urology, 2022, 82, 223-232.	0.9	17
97	Neurotrophins in the Lower Urinary Tract: Becoming of Age. Current Neuropharmacology, 2011, 9, 553-558.	1.4	16
98	Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type a injection. BMC Urology, 2012, 12, 1.	0.6	16
99	Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). International Journal of Urology, 2016, 23, 572-579.	0.5	16
100	Pathophysiological mechanisms in detrusor underactivity: Novel experimental findings. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 92-98.	0.6	15
101	The Impact of Chronic Pelvic Ischemia on LUTS and Urinary Levels of Neuroinflammatory, Inflammatory, and Oxidative Stress Markers in Elderly Men: A Case-control Study. Urology, 2019, 123, 230-234.	0.5	15
102	Unilateral Adrenal Hyperplasia. Southern Medical Journal, 1994, 87, 664-667.	0.3	14
103	Î±1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?. Advances in Therapy, 2016, 33, 2110-2121.	1.3	14
104	Evidence for an urethroâ€vesical crosstalk mediated by serotonin. Neurourology and Urodynamics, 2018, 37, 2389-2397.	0.8	14
105	Effect of Water Avoidance Stress on serum and urinary NGF levels in rats: diagnostic and therapeutic implications for BPS/IC patients. Scientific Reports, 2019, 9, 14113.	1.6	14
106	Preclinical models of endometriosis and interstitial cystitis/bladder pain syndrome: an Innovative Medicines Initiative-PainCare initiative to improve their value for translational research in pelvic pain. Pain, 2021, 162, 2349-2365.	2.0	14
107	New Concepts and Pathophysiology of Lower Urinary Tract Symptoms in Men. European Urology Supplements, 2010, 9, 472-476.	0.1	13
108	The medical treatment of overactive bladder, including current and future treatments. Expert Opinion on Pharmacotherapy, 2011, 12, 1041-1055.	0.9	13

#	Article	IF	Citations
109	Cohort Profile: The Maule Cohort (MAUCO). International Journal of Epidemiology, 2020, 49, 760-761i.	0.9	13
110	Current pharmacotherapy of overactive bladder. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 1091-1107.	0.7	13
111	From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis. International Journal of Women's Health, 2015, 7, 735.	1.1	12
112	Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 263-272.	1.4	12
113	Sites of renal pain processing in the rat spinal cord. A c-fos study using a percutaneous method to perform ureteral obstruction. Journal of the Autonomic Nervous System, 1997, 67, 60-66.	1.9	11
114	Effects of early intravesical administration of resiniferatoxin to spinal cordâ€injured rats in neurogenic detrusor overactivity. Neurourology and Urodynamics, 2019, 38, 1540-1550.	0.8	11
115	A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid, 2020, 30, 704-712.	2.4	11
116	Use of botulinum toxin for genitourinary conditions: What is the evidence?. Toxicon, 2015, 107, 141-147.	0.8	10
117	Renal Cell Carcinoma with Venous Thrombus: Should Surgery Be Offered When Metastasis Is Present at Diagnosis?. Urologia Internationalis, 2018, 101, 387-390.	0.6	10
118	Artificial urinary sphincter or a second adjustable transobturator male systemÂoffer equivalent outcomes in patients whom required revision on the initial ATOMS device: An international multiâ€institutional experience. Neurourology and Urodynamics, 2021, 40, 897-909.	0.8	10
119	Does baseline total testosterone improve the yielding of prostate cancer screening?. European Journal of Cancer, 2012, 48, 1657-1663.	1.3	9
120	Expression of cleaved SNAPâ€25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice. Neurourology and Urodynamics, 2017, 36, 86-90.	0.8	9
121	Underactive bladder in aging rats is associated with a reduced number of serotoninâ€expressing cells in the urethra and is improved by serotonin application to the urethra. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 248-254.	0.6	9
122	Modulation of Urinary Bladder Innervation: TRPV1 and Botulinum Toxin A. Handbook of Experimental Pharmacology, 2011, , 345-374.	0.9	9
123	Sympathetic nervous system and chronic bladder pain: a new tune for an old song. Translational Andrology and Urology, 2015, 4, 534-42.	0.6	9
124	Pharmacology of the lower urinary tract: update on LUTS treatment. Therapeutic Advances in Urology, 2020, 12, 175628722092242.	0.9	8
125	The Effect Of Intravesical Resiniferatoxin In Patients With Idiopathic Detrusor Instability Suggests That Involuntary Detrusor Contractions Are Triggered By C-Fiber Input. Journal of Urology, 2002, , 575-579.	0.2	8
126	Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?. European Journal of Cancer Prevention, 2014, 23, 166-172.	0.6	7

#	Article	IF	Citations
127	Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure. Urology, 2017, 99, 49-56.	0.5	7
128	Vascular endothelial growth factor (VEGF) and prostate pathology. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2010, 36, 430-438.	0.7	6
129	The Future of Pharmacologic Treatment for Bladder Pain Syndrome/Interstitial Cystitis: Lessons From a Meta-Analysis. European Urology, 2012, 61, 54-55.	0.9	6
130	Overactive Bladder: Pathophysiology, Diagnostics, and Therapies. Advances in Urology, 2011, 2011, 1-1.	0.6	5
131	Intrarenal artery pseudoaneurysm after blunt abdominal trauma: a case report of successful superselective angioembolization. Research and Reports in Urology, 2014, 6, 17.	0.6	5
132	Position of the Iberoâ€American Society of Neurourology and Urogynecology in relation to the use of synthetic suburethral meshes for the surgical treatment of female stress incontinence. Neurourology and Urodynamics, 2020, 39, 464-469.	0.8	5
133	ATOMS (Adjustable Transobturator Male System) Is an Effective and Safe Second-Line Treatment Option for Recurrent Urinary Incontinence after Implantation of an AdVance/AdVance XP Fixed Male Sling? A Multicenter Cohort Analysis. Journal of Clinical Medicine, 2022, 11, 81.	1.0	5
134	Mini-Arc for the Treatment of Female Stress Urinary Incontinence: Long-Term Prospective Evaluation by Patient Reported Outcomes. ISRN Urology, 2014, 2014, 1-4.	1.5	4
135	Acute Transient Myopia With Shallowing of the Anterior Chamber Induced by Sulfamethoxazole in a Patient With Pseudoxanthoma Elasticum. Journal of Glaucoma, 2014, 23, 415-417.	0.8	4
136	Treatment of Non-neurogenic Lower Urinary Tract Symptomsâ€"A Review of Key Publications from 2018 Onward. European Urology Focus, 2021, 7, 1438-1447.	1.6	4
137	Mini-Slings: Do They Stand the Test of Time? A 10-Year Cohort. Urologia Internationalis, 2021, 105, 143-147.	0.6	4
138	Adjustable Transobturator Male System (ATOMS) Infection: Causative Organisms and Clinical Profile. Urology, 2021, 157, 120-127.	0.5	4
139	Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients. , 2022, 48, 82-87.		4
140	DU Is Induced by Low Levels of Urinary ATP in a Rat Model of Partial Bladder Outlet Obstruction: The Incidence of Both Events Decreases after Deobstruction. Advances in Urology, 2022, 2022, 1-6.	0.6	4
141	TREATMENT OF PRIAPISM. Lancet, The, 1984, 324, 1348.	6.3	3
142	The Motion: Antimuscarinics are the Mainstay of Therapy for Overactive Bladder. European Urology, 2008, 54, 226-230.	0.9	3
143	Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. European Urology Focus, 2016, 2, 329-331.	1.6	3
144	Position of Iberoâ€American Society of Neurourology and UroGynecology (SINUG) on the use of vaginal meshes in pelvic organ prolapse. Neurourology and Urodynamics, 2020, 39, 1020-1025.	0.8	3

#	Article	IF	Citations
145	The Role of Urinary VEGF in Observational Studies of BPS/IC Patients: A Systematic Review. Diagnostics, 2022, 12, 1037.	1.3	2
146	Intravesical strategies to manage the neurogenic bladder. Current Bladder Dysfunction Reports, 2008, 3, 133-139.	0.2	1
147	Transient receptor potential channel: a reality that still requires many years of scientific efforts. BJU International, 2015, 115, 676-677.	1.3	1
148	Evaluation of the Donor After Brain Death and Technique for Organ Procurement. European Urology Supplements, 2016, 15, 390-396.	0.1	1
149	Treatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019. Current Opinion in Urology, 2020, 30, 486-490.	0.9	1
150	TRPV1 agonist therapies in bladder diseases. , 2005, , 211-225.		1
151	Kidney Hemorrhage After Renal Biopsy Treated by Percutaneous Superselective Segmental Renal Artery Embolization. UroToday International Journal, 2009, 02, .	0.1	1
152	Re: Liu L, Mansfield KJ, Kristiana I, et al. 2007. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol Urodynam 26:433â€“438. Neurourology and Urodynamics, 2007, 26, 439-439.	0.8	0
153	Editorial Comment on: Effect of Thalamic Deep Brain Stimulation on Lower Urinary Tract Function. European Urology, 2008, 53, 612.	0.9	0
154	Reply to Tomasz Drewa, Zbigniew Wolski and Janusz Tyloch's Letter to the Editor re: JoÃ£o Silva, Rui Pinto, Tiago Carvallho, et al. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. Eur Urol 2009;56:134â€“41. European Urology, 2009, 56, e28-e29.	0.9	0
155	Controversies in Urology (CURy): What Is It All About?. European Urology Supplements, 2009, 8, 711.	0.1	0
156	TRP Channels in the Genitourinary Tract. Methods in Pharmacology and Toxicology, 2012, , 373-395.	0.1	0
157	Biomarkers in the Overactive Bladder Syndrome. , 0, , .		0
158	Single Incision Slings: Is There a Role?. Current Bladder Dysfunction Reports, 2013, 8, 19-24.	0.2	0
159	Intravesical Capsaicin and Resiniferatoxin for Bladder Disorders. , 2015, , 119-127.		0
160	Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). European Urology, 2015, 67, 1189-1190.	0.9	0
161	Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European Urology, 2016, 70, 892.	0.9	0
162	Author Reply. Urology, 2017, 99, 55-56.	0.5	0

#	Article	IF	Citations
163	Minimally Invasive Treatments. , 2018, , 387-404.		0
164	Botulinum Toxin Injections in theÂBladder and Urethral Sphincter. , 2019, , 291-298.		0
165	Re: European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. European Urology, 2021, 79, 427.	0.9	0
166	Kidney transplantation from donation after circulatory death using abdominal normothermic oxygenated circulation: are the outcomes equivalent?. International Urology and Nephrology, 2021, 53, 1355-1359.	0.6	0
167	Laparoscopic Partial Nephroureterectomy for Duplex Kidney and Ureter with Megaureter Serving a Hydronephrotic Excluded Upper Pole: A Case Report. UroToday International Journal, 2008, 01, .	0.1	0
168	Editorial Comment. Journal of Urology, 2020, 204, 323-323.	0.2	0